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Abstract 
PTMs (posttranslational modifications) such as ubiquitylation, sumoylation, acetylation and protein methylation are 
pivotal modifiers that determine the activation, deactivation or subcellular localization of signaling proteins, facili-
tating the initiation, amplification and transduction of signaling. Accumulating evidence suggest that several key 
signaling molecules in Hippo signaling pathway are tightly regulated by various types of PTMs. Malfunction of these 
critical signaling modules such as YAP/TAZ, MAT1/2 and LATS1/2 due to deregulated PTMs has been linked to a variety 
of human diseases such as cancer. In this review article, we summarized the current understanding of the impact of 
PTMs in regulating Hippo signaling pathway and further discussed the potential therapeutic intervention from the 
view of PTMs and Hippo pathway.
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Background
The impact of Hippo signaling pathway has been linked 
to a variety of critical biological processes and human 
diseases, including organ growth control, stem cell func-
tion, tissue regeneration and tumor suppression. Signal-
ing modules in the Hippo pathway are tightly regulated 
in order to orchestrate the organ size and cellular prolif-
eration during the development as well as homeostasis. 
While regulation of Hippo cascade can be achieved at 
various levels such as gene replication, transcription and 
protein translation, increasing emerging evidence has 
drawn our attention to posttranslational modifications 
(PTMs). PTMs converts the properties of functional 
protein through a series manners, including proteolytic 
cleavage, the  addition of a modifying group to one or 
more amino acid, which result in alteration of protein 
activity, subcellular localization, turnover, and interac-
tions with partner proteins. Malfunction of PTMs in 
yes-associated protein (YAP)/TAZ, a critical signaling 
node in Hippo pathway, could directly drive tumor ini-
tiation and invasion. This review aims to summarize the 
recently expanded understanding of PTMs in regulating 
Hippo signaling pathway. We will discuss how dysfunc-
tion of Hippo cascade due to the deregulated PTMs 
contributes to tumorigenesis and the current strategies 
of anti-cancer therapeutics through targeting the Hippo 
signaling pathway.
Overview of the Hippo pathway
Kinases cascade of Hippo pathway in mammals
The classic Hippo pathway reveals the pivotal roles of 
PTMs in biological processes, especially phosphorylation 
and ubiquitination. The core of the Hippo pathway com-
prises a highly conserved signaling module that functions 
similarly in mammals and in Drosophila melanogaster. 
Since the discovery of the serine/threonine kinases Mam-
malian Ste20-like kinases (MST1/2) and Large tumor 
suppressor (LATS1/2) in humans (known as the Hpo and 
Warts kinases in fruit flies respectively), many additional 
components of the Hippo pathway have been identified, 
and a complex signaling cascade has emerged which 
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integrates multiple upstream inputs from the plasma 
membrane into the nucleus, including the scaffolding 
protein Salvador homolog 1 (SAV1; Salvador in fruit flies, 
which interacts with MST1 and MST2) and the scaffold-
ing proteins MOB kinase activator 1A (MOB1A) and 
MOB1B (Mats in fruit fly, which interact with LATS1 and 
LATS2, respectively) [1].
When the Hippo pathway is on, MST1/2 phosphoryl-
ates LATS1/2 through their SARAH coiled-coil domains. 
It also phosphorylates MOB1, which enhances MOB1’s 
ability to bind and activate LATS1/2. The LATS1/2 phos-
phorylation of YAP/TAZ (Yki in fruit flies) is a key event 
in the canonical Hippo pathway [2]. LATS1/2 phospho-
rylates YAP at S127 and TAZ at S89 to enhance cytoplas-
mic retention of YAP/TAZ by increasing the interaction 
between YAP/TAZ and 14-3-3 protein. When the Hippo 
pathway is off, the final effectors of Hippo pathway—tran-
scriptional co-activators YAP and TAZ—are translocated 
into nucleus and bind to DNA via forming complexes 
with transcriptional enhancer factor TEFs (TEAD1-
TEAD4; scalloped in fruit flies). They also bind to other 
transcription factors such as SMADs, T-box transcrip-
tion factor 5 (TBX5), RUNT-related transcription factor 
1 (RUNX1) and RUNX2 as well as Tumor protein p73 
to regulate gene expression. As the major downstream 
effector of the tumor suppressing Hippo pathway, YAP/
TAZ were at first recognized as oncogenes. Elevated 
YAP/TAZ expression and nuclear localization have been 
observed in multiple types of human cancers, including 
which located in breast, lung, liver, colon, cervix, ovary, 
and esophagus [3–5]. However, recent data suggest an 
interesting hypothesis that YAP also has tumor suppres-
sor function in certain contexts [6, 7].
Upstream regulators of Hippo pathway
The Hippo pathway bears many upstream regulators 
that feed into the serine/threonine kinases MST1/2 
and LATS1/2. PTMs regulation network is described 
in Fig.  1. Most well-known ones are Merlin, RAS asso-
ciation domain-containing family proteins (RASSFs) and 
protein kidney and brain expressed protein (KIBRA).
Merlin is a cytoskeletal protein and was identified as 
a tumor suppressor underlying Neurofibromatosis type 
II. Merlin contains a conserved FERM domain and was 
reported to be an upstream regulator of Hippo path-
way [8]. Recently, Merlin was found to directly bind and 
recruit LATS to the plasma membrane and promote 
LATS phosphorylation via the MST-SAV kinase complex, 
suggesting an important role of Merlin in activating the 
Hippo-pathway [9].
In Drosophila, dRASSF competes with Sav for Hpo 
and recruits a PP2A complex (dSTRIPAK) to dephos-
phorylate and inactivate Hpo [10]. However, multiple 
RASSF isoforms in mammals showed different roles on 
the Hippo pathway, suggesting a divergent role through 
evolution. RASSF6 inhibited MST2 and antagonized 
Hippo signaling in a manner similar to that of dRASSF 
[11]. RASSF1 and RASSF5 stimulate Hippo signaling and 
play a distinct role from dRASSF. They bind the MST 
and counteract dephosphorylation, then activate NDR1, 
NDR2, and LATS1 to induce apoptosis [12, 13].
KIBRA was identified as a regulator of the Hippo path-
way recently. In Drosophila, Kibra functions together 
with Mer (homolog merlin in mammals) and Ex in a 
protein complex and regulates the Hippo kinase cascade 
via direct binding to Hpo and Sav [14]. In addition to the 
regulation of MST1/2, KIBRA directly regulates LATS1/2 
kinase activity by modulating the phosphorylation and 
stabilizes LATS2 by inhibiting its ubiquitination [15].
In this Review, we largely refer to Hippo signaling com-
ponents using the mammalian nomenclature, and the D. 
melanogaster components are listed in Table 1.
Post‑translational modification of Hippo pathway
The Hippo pathway is considered to be in the active 
state when the MST and LATS kinases are active [16]. 
The MST1/2, aided by their regulatory protein SAV1, 
phosphorylates and activates the LATS kinases and 
MOB1A/B. The activated LATS1/2 in turn phosphoryl-
ates their downstream targets YAP and TAZ, leading to 
these two transcriptional co-activators in their nuclear 
export, cytoplasmic retention and/or proteasomal deg-
radation. TEADs, without YAP and TAZ interaction, 
form complexes with the transcription cofactor vestigial-
like protein 4 (VGL4), repressing target gene expression 
involved in cell proliferation. Thus, when the Hippo path-
way is activated, YAP/TAZ activity is inhibited, and YAP/
TAZ-driven gene expression is suppressed. Inversely, 
YAP and TAZ accumulate in the nucleus when the activ-
ity of upstream of Hippo pathway is inhibited, forming 
complexes with TEADs or other transcription factors. In 
this regard, the Hippo pathway acts primarily by inhibit-
ing the nuclear functions of YAP and TAZ. Main PTMs 
of core components are described in Fig. 2; Table 1.
Phosphorylation
The fate of YAP/TAZ mainly decided by the phosphoryl-
ation status, determining their protein stability, activity 
and subcellular location.
LATS1/2 phosphorylate YAP at five serine residues 
(S61, S109, S127, S164 and S397) and TAZ has four of 
these sites (S66, S89, S117 and S311) [17]. Among these 
residues, S127 (S89 in TAZ) and S397 (S311 in TAZ) 
are key phosphorylation sites in suppressing YAP/TAZ 
oncogenic activity. The former is responsible for the 
spatial regulation (nucleo-cytoplasmic shuttling), while 
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Fig. 1 PTMs regulation of Hippo pathway. Left top pink region the canonical inhibitory kinase module of Hippo pathway. A kinase cascade compris-
ing MST and LATS phosphorylates YAP and TAZ. The phosphorylated YAP and TAZ bind to 14-3-3 and are sequestered in the cytosol. Monomethyl-
ated YAP via Set7 is also critical for cytoplasmic retention. Merlin activates Hippo pathway via binding LATS and inhibiting CRL4DCAF1 E3 ubiquitin 
ligase. TAO3 activates MST by phosphorylation in the same sites as those autophosphorylation sites of MST. Left bottom grey region Proliferation 
is induced when Hippo pathway is off. YAP and TAZ are translocated into nucleus and bind to DNA via forming complexes with Transcriptional 
enhancer factor TEFs (TEAD1-TEAD4) and other transcription factors. Left bottom region YAP mainly mediates p73-dependent pro-apoptotic gene 
transcription in some situation such as DNA damage irritation. PML recruits YAP to the nuclear body and stabilizes p73. C-Abl promotes the associa-
tion of YAP with p73, promoting apoptosis. ①NEK1/CK1ε/δ for TAZ
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Table 1 Post-translational modification controlling hippo pathway core components
Core component  
(D. melanogaster protein)
Enzyme Regulatory sites Function
MST1/2 (Hpo) PI3K/Akt1 T120-p, T387-p Prevention of caspase-mediated cleavage 
of MST1
Autophosphorylation T183-pa MST activation
JNK1 S82-p Enhancement of MST1-mediated  
pro-apoptotic signaling
mTOR T120-p Loss of MST1 function
c-Abl Y433-p Inhibition of degradation
TAO3b MST activation
PP2A T183-depa
CHIP Ubiquitination Protein degradation
SAV1 (Sav) MST2 T26-p, S27-p, S36-p, S269-p Activation
SIK2 and SIK3 S413-pc Antagonizing Hpo pathway activity
LATS1/2(Wts) MST1/2 s909-p, T1079-pd Enzymatic activity
NUAK1 s464-p Protein stability
KIBRA T1079-pd Kinase activity
Itch Ubiquitination Protein degradation
CRL4DCAF1 Ubiquitination Protein degradation
LATS1 WWP1 Ubiquitination Protein degradation
Nedd4 Ubiquitination Protein degradation
LATS2 CHK1/2 S408-p Cell cycle regulation, apoptosis
SIAH1/2 Ubiquitination Protein degradation
Aurora A S83-p, S380-p Intracellular localization
MOB1A, MOB1B (Mats) MTS1/2 T12-p, T35-p, T74-p Molecular association
praja2 Ubiquitination Protein degradation
YAP (Yki) LATS1/2 S61-p, S109-p, S164-p The cytoplasmic retention
S127-p The binding of 14-3-3 
S397-pe Facilitates the binding of CK1δ/ε, leading 
to further serine phosphorylations
CK1ε/δ S400-p, S403-pf Generates a “phosphodegron” together 
with S397
c-Abl Y407-pg Promotes p73-dependent pro-apoptotic 
transcription
Src/YES1 Y407-p Induces assembly of the β-catenin–YAP 
complex
CDK1 T119-p, S289-p, S367-p Cell cycle regulation
NDR1/2 S127-p The cytoplasmic retention
JNK T119-p, S138-p, T154-p, S317-p,  
T362-p
Inducing YAP to play dual role in different 
cell contexts
SCFβ-TRCP Ubiquitination Protein degradation
Fbxw7 Ubiquitination Protein degradation
Set7 K494-me Cytoplasmic retention
CBP/p300 K494-ac; K497-ac Altered nuclear activity
PML K97-sumo, K280-sumoh Stabilizes YAP1 by sumoylation and 
enhances p73-dependent transcription
TAZ LATS1/2 S66-p, S117-p Cytoplasmic retention
S89-p The binding of 14-3-3 
S311-p Facilitates the binding of CK1δ/ε, leading 
to further serine phosphorylations
GSK3-beta S58-p, S62-p Degradation
NEK1/CK1ε/δ S314-p Degradation/β-TrCP recruitment
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the latter is linked to the temporal regulation (degrada-
tion). Phosphorylation of S397 in YAP (S311 in TAZ) by 
LATS1/2 has been linked to regulation of protein stabil-
ity, as it primes for the additional phosphorylation in YAP 
on S400 and possibly on S403 (S314 in TAZ) by CK1ε/δ, 
which generates a “phosphodegron motif” located in the 
C-terminal region of YAP/TAZ with pS397/pS311. This 
motif targets YAP/TAZ for polyubiquitination by recog-
nizing and recruiting β-TrCP, a key adaptor of SCF E3 
ubiquitin ligase, in this area and consequently facilitates 
proteasomal degradation. Being independent of LATS 
phosphorylation, GSK3-β phosphorylates of TAZ at S62, 
S58 in response to PI3K inhibition, finally forming N-ter-
minal phosphodegron recognized by β-TrCP [18].
Phosphorylation of LATS also affect YAP/TAZ’s sub-
cellular localization. Phosphorylation on S127 in YAP 
(S89 in TAZ) results in a binding site for 14-3-3 proteins, 
which would then keep YAP/TAZ in the cytoplasm. 
However, the sequestration of YAP/TAZ in the cytoplasm 
is not only achieved by S127 phosphorylation. Some 
observations indicate that there may be additional PTMs 
retaining YAP in the cytoplasm. Nuclear Dbf2-related 
kinases (NDR1/2) were found to phosphorylate S127 of 
YAP leading to the cytoplasmic retention and contribute 
to apoptosis and cell cycle regulation [19]. PP1A coupled 
with ASPP2 antagonizes the function of LATS to regulate 
the reversible phosphorylation of YAP/TAZ, increasing 
YAP/TAZ-dependent gene expression [20].
Apart from the classic LATS phosphorylation, YAP/
TAZ are also targets of other kinases. JUN N-terminal 
kinases (JNK1 and JNK2) are identified as robust YAP 
kinases, with five novel phosphorylation sites on YAP 
identified: T119, S138, T154, S317 and T362 [21]. Upon 
UV irradiation, JNKs is stimulated to phosphorylate YAP. 
YAP to play a  dual role in different cell contexts: YAP 
plays a protective role in keratinocytes but promotes UV-
induced cell death in BWT skin squamous cell carcino-
mas, determining by the isoforms of p63 or p73 it binds. 
However, the same regulatory site, YAP pY357, plays two 
opposite roles based on the nature of the tyrosine kinase, 
either c-Abl or YES1. Cross-talking with Wnt/β-catenin 
pathway, YES1-mediated YAP modification is oncogenic 
and induces assembly of the β-catenin–YAP complex 
coactivating TBX5 target genes [22]. C-Abl, in the con-
trary, antagonizes the YAP oncogenic function, depresses 
YAP–TEAD-induced transcription and increases the 
binding affinity of YAP1 and p73, activating proapop-
totic targets [23]. The nucleus dephosphatase PTPN14 
could dephosphorylate YAP Y357 phosphorylation to 
induce cell proliferation [24]. In line, HIPK2 kinase regu-
lates YAP abundance independent of its ability to regu-
late SCFβ-TrCP and in parallel to LATS1 and LATS2 to 
enhance YAP’s activity [25]. In addition, in mammalian 
cells, HIPK2 possibly influences YAP activity by promot-
ing YAP abundance, whereas in D. melanogaster tissues, 
Hipk affects Yki localization.
Phosphorylation status of other core components are 
under regulation of kinases and phosphatases as well. 
In response to apoptotic or stress stimuli, MST1/2 is 
autophosphorylated at multiple sites in the activation loop, 
which results in the activation of MST1/2. Among these 
autophosphorylation sites, phosphorylation at T183 and 
T180 is essential for MST1 and MST2 activation, respec-
tively [26]. These sites can also be trans-phosphorylated 
by the Ste20 family kinase TAO kinase-3 (TAO3), result-
ing in MST activation [27]. Besides autophosphorylation, 
MST1/2 are also regulated by trans-phosphorylation by 
protein kinases such as Akt, mTOR, JNK1, c-Abl. Akt 
Table 1 continued
Core component  
(D. melanogaster protein)
Enzyme Regulatory sites Function
c-Abl Y321-p Altered nuclear activity
PP1 S89-dep,S311-dep Promotes TAZ nuclear translocation, and 
stabilizes TAZ by disrupting the binding 
to the SCF E3 ubiquitin ligase
The Hippo pathway acts primarily by inhibiting the nuclear functions of YAP and TAZ. Main PTMs of core components are described in Fig. 2; Table 1.)
p phosphorylation; dep dephosphorylation; me methylation; ac acetylation; sumo sumoylation
a  T180-p in MST2
b  Tao1 phosphorylates T195-p of Hpo
c  Phosphorylation of Sav at Ser 413 in Drosophila
d  Thr1079 in Lats1 and Thr1041 in Lats2
e  S381 of YAP1 iso2 corresponds to S397 of YAP1
f  S384, S387 of YAP1 iso2 corresponds to S400, S403 of YAP1
g  Y357 of YAP1 iso3 corresponds to S407 of YAP1
h  K242 of YAP1 iso3 corresponds to K280 of YAP1
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binds to the C-terminus of MST1 and phosphorylates 
MST1 at the T120 and T387 residues. Phosphorylation 
of MST1 by Akt prevents caspase-mediated cleavage of 
MST1 and hence prevents activation of MST1 [28]. The 
mTOR signaling pathway also regulates MST1 phospho-
rylation at T120 and that this phosphorylation results in 
loss of MST1 function in prostate cancer cells [29]. Phos-
phorylation of MST1 on S82 by JNK1 enhances MST1-
mediated pro-apoptotic signaling [30]. C-Abl inhibits the 
degradation of MST1 through CHIP and, secondly, trig-
gers association between MST1 and FOXO3, thereby acti-
vating the MST1-FOXO signaling [31].
Ubiquitination
Besides the classical SCFβ-TrCP induced ubiquitination 
mentioned above, F-Box and WD repeat domain con-
taining 7 (Fbxw7) was found to regulate YAP protein 
abundance by targeting YAP for ubiquitination and pro-
teasomal degradation in hepatocyte carcinoma [32].
Notably, ubiquitination is more ubiquitous among the 
kinases of YAP/TAZ. Convincing evidence shows that the 
protein levels of LATS1/2 kinases are controlled by Itch 
E3 ubiquitin ligase-mediated degradation [33, 34]. Recent 
work shows that E3 ligase CRL4DCAF1-mediated inhibi-
tion of LATS1/2 in the nucleus is associated with Merlin/
NF2 loss-driven tumorigenesis. Upon translocation into 
the nucleus, this form of Merlin binds to DCAF1 and sup-
presses CRL4DCAF1 activity, different from Merlin activity 
on core Hippo kinase cascade in the  cytoplasm [35]. In 
addition, LATS1 and LATS2 are found to own their unique 
E3 ligases in different studies. Neuronally expressed 
developmentally downregulated 4 (Nedd4) and WWP1 
E3 ligases inhibit the activity of LATS1 by targeting it for 
ubiquitin-mediated degradation, which turn out to pro-
mote tumorigenicity in different types of tumors, while 
SIAH1 and SIAH2 E3 ligases regulate LATS2’s stability in 
response to hypoxia [36, 37]. The co-factor of LATS1/2, 
MOB1, goes through proteolysis by E3 ligase praja2, which 
attenuates Hippo signaling and supports glioblastoma [38].
MST1 is also reported to be recognized by E3 ligase C 
terminus of Hsc70-interacting protein (CHIP). Inhibi-
tion of c-Abl promotes the degradation of MST1 through 
CHIP-mediated ubiquitination, and thereby attenuates 
cell death [39].
Fig. 2 Schematic domain structure and PTMs sites of Hippo pathway core components. SARAH Sav/Rassf/Hpo domain; NES nuclear- exporting 
sequence; WW WW domain; UBA Ubiquitin-associated domain; PBD protein binding domain; HM hydrophobic motif; P-rich proline-rich region; C–C 
coiled-coil domain; PDZ-binding PDZ-binding motif. PTMs residue site details are listed in Table 1
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In contrast with E3 ligase, Deubiquitinases (DUBs) 
can remove monoubiquitin or polyubiquitin chain from 
the substrate, rescuing proteins from degradation fate or 
changing proteins’ activity state. CYLD is found to nega-
tively regulate Hippo signaling by limiting Hpo phospho-
rylation at T195 in Drosophila, increasing Yki’s activity 
[40]. However, it remains to be determined whether the 
deubiquitinase activity of dCYLD is essential for limiting 
Hpo phosphorylation.
Sumoylation
Eleonora Lapi and colleagues find that PML and YAP 
physically interact through their PVPVY and WW 
domains, respectively, causing PML-mediated sumoyla-
tion and stabilization of YAP in a pro-apoptotic autoreg-
ulatory feedback loop between PML, YAP, and p73 [41].
Acetylation
Specifically, the YAP acetylation cycle is a balance 
between acetylation and deacetylation and is subjected 
to regulation by the transcriptional coactivator activity 
of human YAP. Nishita and colleagues provide impor-
tant evidence that suggested YAP acetylation occurs on 
specific and highly conserved C-terminal lysine residues 
and is mediated by the nuclear acetyltransferases CREB 
binding protein (CBP) and p300 [42]. Conversely, the 
nuclear deacetylase NAD-dependent protein deacety-
lase sirtuin-1 (SIRT1) is responsible for YAP deacetyla-
tion. Intriguingly, this kind of YAP acetylation is induced 
specifically by S(N)2 alkylating agents and not by other 
DNA-damaging stimuli [43].
Protein methylation
Methylation of non-histone proteins is emerging as 
a regulatory mechanism to control protein function. 
Monomethylation of lysine 494 of Yap via Set7 is critical 
for cytoplasmic retention [44]. Thus this methylation-
dependent checkpoint in the Hippo pathway may play a 
inhibitory role in YAP activation.
PTMs of Hippo pathway in human cancers
The Hippo pathway regulated and is regulated by sev-
eral cellular properties that are linked to tumorigenesis 
and progression. However, Hippo pathway genes are 
infrequently germline or somatically mutated in human 
cancers whether in targeted or whole genome sequenc-
ing research; this is especially true of the core Hippo 
pathway genes, example for neurofibromin 2 (NF2; also 
known as Merlin) in neurofibromatosis and malignant 
mesothelioma, and LATS2 in malignant mesothelioma. 
At the same time, the deregulation of the Hippo pathway 
has been reported at a high frequency in a broad range of 
different human carcinomas, including breast, lung, liver, 
colorectal, ovarian and prostate cancers, and it often cor-
relates with poor patient prognosis. In light of these find-
ings, we can imagine the probable pivotal role of PTMs of 
Hippo pathway in human cancers.
Breast cancer
Elevated TAZ expression is observed in more than 20 % 
of breast cancers, especially invasive ductal carcinomas. 
And overexpression of TAZ in “normal” mammary cell 
line MCF10A cells promotes cell proliferation, EMT, and 
oncogenesis. Mutation of the N-terminal phosphodegron 
created by GSK3-β will increases TAZ activity in induc-
ing EMT in MCF10A cells [18].
Itch and WWP1 have been found negatively regulate 
LATS1 stability in breast cancer cells [33, 36]. Mean-
while, Ring-finger E3 ligase SIAH1, activated by HIF-1, is 
required for the hypoxia-induced ubiquitination and pro-
teasome-dependent degradation of LATS2 and trigger 
nuclear localization of TAZ, leading to the breast cancer 
stem cells (BCSCs) maintenance. Similarly, SIAH2 pro-
motes tumour growth through downregulation of LATS2 
in breast cancer cells [37] and SIAH2 knockdown xeno-
graft tumor growth is much suppressed.
Hepatocellular carcinoma (HCC)
Fbxw7 was found to regulate YAP protein abundance in 
HCC [32]. Fbxw7 expression was impaired in HCC tis-
sues and loss of Fbxw7 expression was correlated with 
poor clinicopathological features.
The expression of SIRT1 is significantly upregulated in 
the HCC samples, and SIRT1 deacetylates YAP2 protein 
in HCC cells, which increases the YAP2/TEAD4 associa-
tion, leading to YAP2/TEAD4 transcriptional activation 
and upregulated cell growth in HCC cells [43].
Nervous system tumor
In mesothelioma cells with NF2-mutant and derepres-
sion of CRL4DCAF1, cell proliferation, colony formation 
and tumor growth in xenograft mice will all be enhanced 
by inactivating LATS1/2 and, hence, activating YAP in 
the nucleus [35].
Hematological cancers
YAP was markedly downregulated in hematological 
malignancies, including lymphomas, leukemia and mul-
tiple myeloma [45]. In normal haematological cells, YAP1 
forms a complex with the tumour p73 to support the 
transcription of proapoptotic genes, such as BAX and 
PIG3 expression [46]. In multiple myeloma cells, low 
expression of YAP prevents apoptosis in the presence of 
DNA damage in these haematological malignancies. Re-
expression of YAP in multiple myeloma cells with YAP 
deletion or knockdown of MST1 in multiple myeloma 
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cells with wild-type YAP, promoted apoptosis and growth 
arrest [45].
Promising target and therapeutic implication
The PTM deregulation of Hippo pathway signaling in 
cancer triggers us to target these PTM elements in this 
pathway as an anticancer therapeutic strategy. Riskily and 
challengingly, identification of druggable components of 
these regulatory network will present opportunities for 
targeting therapy. For therapeutic strategies to be suc-
cessful, the cancer must be functionally reliant on the 
pathway component that is being targeted.
Kinases and phosphatases
Targeting the kinase cascade of Hippo signaling could be 
by increasing the activities of MST1/2 and/or LATS1/2 
kinases functioning upstream of YAP/TAZ. Instability of 
tumor suppressor kinases and depression of their expres-
sion in Hippo pathway promote downstream transcrip-
tional co-activator YAP/TAZ to carry out their oncogenic 
roles in various tumors. The integrin-linked kinase (ILK) 
plays a role in suppressing the Hippo pathway by phospho-
dependent inactivation of MYPT1 phosphatase leading 
to inactivation of Merlin/MST/LATS key components 
of the Hippo pathway [47]. Using ILK inhibitor QLT0267 
in breast, prostate and colon tumour cells results in the 
activation of the Hippo pathway components MST1 and 
LATS1 with concomitant inactivation of YAP/TAZ and 
TEAD-mediated transcription. HIPKs and SIKs represent 
possible drug targets to blunt YAP/TAZ activity, as both 
kinases promote YAP activity in human cells [25, 48]. The 
G-protein coupled receptor (GPCR) has been reported 
recently link to Hippo-YAP/TAZ pathway [49]. Since many 
currently used therapeutic compounds target GPCR sign-
aling directly or indirectly GPCR-Hippo signaling repre-
sents an attractive druggable target YAP/TAZ [50].
Ubiquitin–Proteasome system
To date, E3 ligase inhibitory compounds have been 
designed and discovered to have tumor suppression 
function, which will be listed as follows (Table 2).
‑Itch
Clomipramine, a tricyclic antidepressant, has been iden-
tified as Itch inhibitor via a high throughput screen for 
small molecular weight inhibitors of the HECT E3 ligase 
[51]. Clomipramine can induce reduction of cancer cell 
growth, and synergism with gemcitabine or mitomycin 
in killing human breast, prostate and bladder cancer cells 
through autophagy blockade. However, Itch is known 
to target multiple proteins for ubiquitination, which 
enhances the complexity of predicting the consequence 
of Itch inhibition in vivo.
‑Nedd4
Amounting evidence has revealed that NEDD4 is fre-
quently overexpressed in a range of human cancers which 
suggests that NEDD4 is a legitimate target for designing 
new drugs to treat human malignancies. Recently, A few 
bicyclic peptides isolated by phage display were demon-
strated to have the capacity in targeting the E2 binding 
sites on the HECT domains of Smurf2, Nedd4, Mule/
Huwe1, and WWP1, and act as specific inhibitors of 
these enzymes in vitro [52]. One of these peptides, Hec-
lin, kills HEK293 cells growing in culture, consistent with 
an essential role for HECT ligase activity in mammalian 
cells.
‑Siah1/2
Proof-of-concept for small molecule inhibition of Siah 
has been obtained with a short protein fragment that 
binds competitively with high affinity to the substrate 
binding site of Siah proteins, and resulted in reduced 
growth of breast cancers and reduced frequency of 
metastases in melanoma. A rational structure-based 
design strategy was successful for the identification of 
novel Siah inhibitors BI-107F7 and BI-107F9, in which 
peptide binding drives specific covalent bond formation 
with the target [53]. X-ray crystallography, mass spec-
trometry and functional data demonstrate that these 
peptide-mimetics are efficient covalent inhibitors of Siah 
and antagonize Siah-dependent regulation of Erk and Hif 
signaling in cells.
Conclusion and future prospects
Increasing evidence has attracted significant atten-
tion to the role of Hippo signaling in the developmen-
tal control as well as tumor initiation, invasion and drug 
Table 2 Compounds targeting Hippo pathway PTMs regu-
lators
Target Compounds Function
ILK QLT0267 Activation of the Hippo pathway compo-
nents MST1 and LATS1 with concomitant 
inactivation of YAP/TAZ and TEAD-mediated 
transcription
Itch Clomipramine A clinically useful antidepressant drug. The 
effects in cancer cells treated with clomi-
pramine included reduction of cell growth, 
and synergism with gemcitabine or mitomy-
cin in killing cancer cells through autophagy 
blockade
Nedd4 Heclin Bicyclic peptides, kills HEK293 cells growing 
in culture
SIAH1/2 BI-107F7 Peptide-mimetics, efficient covalent inhibitors 
of Siah and antagonize Siah-dependent 
regulation of Erk and Hif signaling in cell
BI-107F9
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resistance. In this review we summarized and discussed 
the importance of posttranslational modification such 
as phosphorylation, ubiquitylation, acetylation and pro-
tein methylation in orchestrating upstream signaling 
transduction, YAP/TAZ nuclear locational and tran-
scriptional activation. Disrupted posttranslational modi-
fications have been tightly connected to the aberrant 
development and different types of tumor formation. 
Emerging development of novel chemical inhibitors of 
various signaling molecules in the Hippo-pathway has 
shed light on next era strategy of anti-cancer therapeu-
tics. In-depth exploration of the impact of posttrans-
lational modifications in regulating Hippo signaling 
pathway opens a new avenue to advance the molecular 
mechanism of tumor initiation, invasion and occurrence, 
which complements well with the present techniques for 
diagnosis and therapeutics.
While previous efforts sketched a reasonable frame-
work of posttranslational modification network in the 
regulation of Hippo signaling pathway, future work from 
the following aspects is necessary to establish a post-
translational modification regulatory circuitry in an 
entire shape. (1) The recent proteomic studies suggested 
possible crosstalk among various types of posttransla-
tional modifications happen on the same protein that 
determines its functional. Thus the development of more 
sophisticated measurement of protein modifications and 
thorough dissection of integrated posttranslational modi-
fications on the same signaling molecule such as YAP/
TAZ will enhance our mechanistic understanding. (2) 
Despite the discovery of the role for a series of modifi-
cation enzymes such as ubiquitin protein ligase, acetyl-
transferase, protein methyltransferase and protein kinase, 
studies for the counteracting enzymes in balancing the 
posttranslational modifications such as deubiquitinase, 
deacetyltransferase, demethyltransferase as well as phos-
phatase need to be carried out. (3) Bioinformatics in data 
mining of TCGA analysis with mutations on the protein 
modifiers or critical site on the substrates that facilitates 
the protein modification will lead to the  foundation of 
the  personalized strategy to combat cancer. (4) Devel-
opment of specific antibodies that recognize specific 
modification sites could result in new biomarkers of early 
diagnosis. (5) Development of inhibitors that prevent the 
abnormal posttranslational modifications could be uti-
lized for chemosensitization or precision therapeutics.
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